BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/26/2026 6:06:22 AM | Browse: 133 | Download: 415
Publication Name World Journal of Radiology
Manuscript ID 116084
Country China
ISSN 1949-8470 (online)
Open Access This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright © The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Letter to the Editor
Article Title Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation
Manuscript Source Invited Manuscript
All Author List Yan Xu, Xiao-Bing Huang and Yong-Gang He
ORCID
Author(s) ORCID Number
Yan Xu http://orcid.org/0000-0001-7319-9223
Xiao-Bing Huang http://orcid.org/0009-0002-3551-9665
Yong-Gang He http://orcid.org/0000-0001-5714-6826
Funding Agency and Grant Number
Corresponding Author Yong-Gang He, Associate Chief Physician, Department of Hepatobiliary, The Second Affiliated Hospital of Army Medical University, No. 83 Xinqiaozheng Street, Chongqing 400037, China. xqyyhyg@tmmu.edu.cn
Key Words Radiotherapy; Bevacizumab; Gastrointestinal cancers; Intestinal perforation; Combination therapy; Toxicity management
Core Tip The combination of radiotherapy and bevacizumab in gastrointestinal cancers offers enhanced efficacy but requires careful management due to an increased risk of intestinal perforation. Strategic patient selection and advanced radiotherapy techniques are essential to balance benefits and risks.
Publish Date 2026-01-26 06:06
Citation

Xu Y, Huang XB, He YG. Radiotherapy combined with bevacizumab in gastrointestinal cancers: Balancing efficacy against the risk of intestinal perforation. World J Radiol 2026; 18(1): 116084

URL https://www.wjgnet.com/1949-8470/full/v18/i1/116084.htm
DOI https://dx.doi.org/10.4329/wjr.v18.i1.116084
Full Article (PDF) WJR-18-116084-with-cover.pdf